The IGF pathway is activated in insulinomas but downregulated in metastatic disease

Endocrine-related Cancer
Mieke HenflingErnst-Jan M Speel

Abstract

Clinical and molecular studies have implicated epidermal growth factor receptor (EGFR), insulin-like growth factor (IGF) and target of rapamycin (mTOR) signaling pathways in the regulation of pancreatic neuroendocrine tumor (PanNET) growth. Interpretation and comparison of these studies is complex due to clinical and molecular tumor heterogeneity. We therefore focused in this study on insulinomas, which we examined for mRNA and protein expression of EGFR, IGF and mTOR signaling pathway components by quantitative real-time PCR (n=48) and immunohistochemistry (n=86). Findings were compared with normal pancreatic islets and correlated with histopathological data and clinical outcome. Insulinomas showed low EGFR and high IGF2 expression. IGFBP2, IGFBP3 and IGFBP6 mRNA levels were 2-4 folds higher than in islets. High protein expression of IGF2, IGF1R and INSR (in 51-92% of the tumors) and low to moderate expression of mTORC1 pathway proteins p-PS6k and p-4EBP1 (7-28% of the tumors) were observed. Correlations were found between 1) ERK1 mRNA expression and that of numerous IGF pathway genes, 2) p-ERK and IGF1R protein expression and 3) decrease of IGF pathway components and both metastatic disease and shorter 10 years disease free s...Continue Reading

References

Jan 20, 1999·European Journal of Clinical Investigation·U WulbrandH Fehmann
Aug 30, 2000·European Journal of Clinical Investigation·U WulbrandH C Fehmann
Dec 5, 2000·International Journal of Cancer. Journal International Du Cancer·B SchnarrD Mayer
Jun 12, 2001·APMIS : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica·A HöögL Grimelius
Sep 28, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Donna E HanselAnirban Maitra
May 28, 2005·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Bettina PapouchadoRicardo V Lloyd
Apr 11, 2006·Molecular Cancer Research : MCR·Susan K MurphyAndrew Berchuck
Aug 26, 2006·Endocrine Reviews·Amir Abbas SamaniPnina Brodt
Dec 19, 2006·Molecular Cancer Therapeutics·Yaguang XiJingfang Ju
Jan 11, 2007·Breast Cancer Research : BCR·Zefang RenWei Zheng
Mar 1, 2008·Cytokine & Growth Factor Reviews·Wendy Chao, Patricia A D'Amore
Mar 14, 2008·The New England Journal of Medicine·Fortunato Ciardiello, Giampaolo Tortora
Nov 18, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Edoardo MissiagliaAldo Scarpa
Dec 17, 2010·Endocrine-related Cancer·Atsuko KasajimaWilko Weichert
Feb 11, 2011·The New England Journal of Medicine·James C YaoUNKNOWN RAD001 in Advanced Neuroendocrine Tumors, Third Trial (RADIANT-3) Study Group
Apr 13, 2012·Expert Opinion on Therapeutic Targets·Ryan D GentzlerLeonidas C Platanias
May 16, 2012·Cancer Discovery·Levi A Garraway, Pasi A Jänne
Jun 12, 2012·Endocrinology and Metabolism Clinics of North America·S John Weroha, Paul Haluska
Jun 20, 2012·Journal of Surgical Oncology·Han-Xiang ZhanJun-Chao Guo
Dec 22, 2012·Gerontology·Daniel BergmanWilhelm Engström
Jan 15, 2013·Disease-a-month : DM·Thiruvengadam MunirajHarry R Aslanian
Aug 28, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Zhi Rong QianMatthew H Kulke
Sep 5, 2013·Journal of Hepato-biliary-pancreatic Sciences·Yoko KomoriSeigo Kitano
Oct 2, 2013·Endocrine-related Cancer·Callum Livingstone
Dec 12, 2013·Nature Communications·Yanan CaoGuang Ning
Apr 12, 2014·Nature Reviews. Cancer·Robert C Baxter
Dec 26, 2015·Lancet·James C YaoUNKNOWN RAD001 in Advanced Neuroendocrine Tumours, Fourth Trial (RADIANT-4) Study Group
Aug 19, 2016·Endocrine-related Cancer·S G CreemersL J Hofland
Oct 21, 2016·Endocrine-related Cancer·Simona FallettaMaria Chiara Zatelli
Feb 16, 2017·Nature·Aldo ScarpaSean M Grimmond

❮ Previous
Next ❯

Citations

Jul 3, 2021·Cells·Rosa Lynn SchmitzSebastian Krug

❮ Previous
Next ❯

Related Concepts

Related Feeds

Adenoma, Islet Cell

Islet Cell Adenoma arises in the islet cells, which are insulin producing cells of the pancreas. These tumors can be either malignant or benign. Discover the latest research on Islet Cell Adenoma here.

Carcinoma, Islet Cell (Keystone)

Islet Cell Carcinoma or Pancreatic Neuroendocrine Tumours arise in the hormone producing cells of the pancreas. These tumors can be either malignant or benign. Discover the latest research on islet cell carcinoma in this feed.

Carcinoma, Islet Cell

Islet Cell Carcinoma or Pancreatic Neuroendocrine Tumours arises in the hormone producing cells of the pancreas. These tumors can be either malignant or benign. Discover the latest research on Islet Cell Carcinoma here.